ASSOCIATION BETWEEN INTERLEUKIN 6 SERUM LEVEL AND NON-ALCOHOLIC FATTY LIVER DISEASE

Abstract

Background. Non-Alcoholic Fatty Liver Disease (NAFLD) emerged as a major health problem throughout the world and is increasing as the prevalence of obesity and diabetes continues to increase and is recognized as a major cause of liver disease-related morbidity and mortality. Adipokine is critically involved in healthy liver physiology and in the pathophysiology of acute and chronic liver disease as an intermediary for liver inflammation, liver cell death, cholestasis, and fibrosis. Interleukin-6 (IL-6) is one of adipokines widely studied recently. IL-6 showed improvement and played an important role in the pathogenesis of NAFLD.

Aim. To determine association of serum Interleukin 6 level with NAFLD and other marker associate with NAFLD.

Methods. Cross-sectional study of 30 consecutive NAFLD patients who came to Adam Malik General Hospital Medan and North Sumatra University Hospital in 2018. NAFLD was diagnosed by abdominal ultrasound. Complete blood count, blood sugar level, parameters of liver function, lipid profile and IL-6 were measured in each subject.

Results. Of the 60 subjects, they are divided into 2 groups; 30 subjects in the NAFLD group and 30 subjects in the NAFLD group. The mean serum IL-6 level in the NAFLD group was 5.1 ± 2.87pg / ml and the control group was 1.9 ± 0.50pg / ml.

Conclusion. There was a significantly higher difference in serum Interleukin 6 (IL-6) levels between the Non Alcoholic Fatty Liver Disease (NAFLD) group and the control group.